Insights+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902...

Insights+ Key Biosimilars Events of September 2021

Insights+ Key Biosimilars Events of September 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Insights+ Key Biosimilars Events of April 2021

Insights+ Key Biosimilars Events of April 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Insights+ Key Biosimilars Events of July 2021

Insights+ Key Biosimilars Events of July 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Insights+ Key Biosimilars Events of February 2021

Insights+ Key Biosimilars Events of February 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Insights+ Key Biosimilars Events of January 2021

Insights+ Key Biosimilars Events of January 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Image